医疗技术公司Senseonics Holdings（SENS）今日盘前大涨5.13%，引起投资者关注。这一涨幅主要源于公司宣布的一项重大融资计划以及战略投资。
据悉，Senseonics周四晚间以每股0.50美元的价格发行了1亿股股票，共筹集5000万美元。同时，制药巨头雅培实验室（Abbott Laboratories）参与了一项私募，以相同价格购买了价值最多2500万美元的股票，使其持有Senseonics约5%的股份。这笔资金将用于支持Eversense 365连续血糖监测系统的持续商业化，并进一步开发公司的产品线。
值得注意的是，Senseonics还终止了此前与高盛达成的5500万美元场内股权销售协议。尽管公司股价近期表现疲软，连续五个交易日下跌，且远低于2月中旬创下的52周高点1.40美元，但此次融资和战略合作仍为公司注入了新的发展动力，获得了市场积极反应。道明高文、巴克莱银行、加拿大皇家银行和莱克街银行共同参与了此次发行，进一步彰显了市场对Senseonics发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.